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6/j.bGraft-versus-host disease (GVHD), mediated by mature T cells present in the donor graft, remains a major
complication after allogeneic peripheral blood stem cell transplantation (PBSCT). Regulatory T cells (Tregs)
(CD41CD25highFoxp31) are believed to maintain tolerance and to inhibit GVHD after allogeneic PBSCT
(allo-PBSCT). In this study, we analyzed the graft CD31/Tregs ratio (gCD3/Tregs R) and evaluated its impact
on acute GVHD (aGVHD) and immunologic recovery after myeloablative allo-PBSCT. We analyzed 65 con-
secutive patients who underwent transplantation with unmanipulated peripheral blood stem cells from an
HLA-identical related donor (n5 45) or an HLA-identical unrelated donor (n5 20). The median CD31 and
Tregs doses administered were 256  106/kg of body weight (range, 67-550  106/kg) and 12  106/kg
(range, 2-21  106/kg), respectively; the median gCD3/Tregs R value was 18 (range, 8-250). Patients
were subdivided into a high gCD3/Tregs R ($36) group (HR; n5 26) and a low gCD3/Tregs R (\36) group
(LR; n5 39). The incidence of aGVHD (grade II-IV) was lower in the LR group compared with the HR group
(8/39 [20%] versus 22/26 [84%]; P\.001). Median cytomegalovirus-specific CD81 T lymphocytes were sig-
nificantly higher in the LR group than in the HR group at 1 month (2 cells/mL versus 0 cells/mL; P\.001), 2
months (6 cells/mL versus 1 cell/mL; P\.001), and 3 months (15 cells/mL versus 3 cells/mL; P\.001) months.
Moreover, cytomegalovirus infection/disease was observed in 15% of patients in the LR group versus 69% of
patients in the HR group (P\.001). At multivariate logistic regression, gCD3/Tregs R was correlated both
with aGVHD (odds ratio, 2.50; 95% confidence interval, 1.30-4.50; P 5 .05) and with cytomegalovirus in-
fection/disease (odds ratio, 2.35; 95% confidence interval, 0.9-5.00; P 5 .05). Taken together, our data
may suggest that the balance in favor of graft Tregs content is able to mediate protective effects against
aGVHD and to maintain an optimal microenviroment for the reconstitution of functional immunity.
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bmt.2011.10.039widespreaduse of this approach in treating hematologic
malignancies [1-3], althoughGVHD is often associated
with the eradication of residual disease and,
consequently, a low frequency of relapse due to graft-
versus-leukemia (GVL) effects [4]. Despite improve-
ments in HLA typing, the incidence of GVHD has
not decreased over the years because of a progressive
expansion of donor options, including donors other
thanHLA-identical matched siblings, peripheral blood
instead of bone marrow as the stem cell source, and
older age of both donors and recipients as candidates
for nonmyeloablative transplantation modalities [5].
Acute GVHD (aGVHD) is triggered by alloreactive
mature donor CD31T cells that recognizeMHC class
I and II molecules on the surface of host cells, as well as
the peptides that they present [6-8]. However, T cell
depletion of the donor graft results in graft failure [9],
prolonged immunosuppression [10], and leukemia887
Table 1. Patient Characteristics
Patients, n 65
Sex, males/females, n (%) 30 (46)/35 (54)
Age, years, median (range) 35 (18-61)
Diagnosis, n (%)
Acute myelogenous leukemia 56 (86)
Acute lymphoblastic leukemia 7 (11)
Chronic myelogenous leukemia 2 (3)
Conditioning regimen: busulfan + cyclophosphamide,
n (%)
65 (100)
Donor, n (%)
Sibling matched donor 45 (69)
Matched unrelated donor 20 (31)
gCD3/Tregs R, n (%)
LR group 39 (60)
HR group 26 (40)
Stem cell source: PBSCs, n (%) 65 (100)
GVHD prophylaxis: cyclosporin + methotrexate, n (%) 65 (100)
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needed to limit theGVHD-related pathological effects
of donor-alloreactive CD31 T cells while maintaining
their GVL effect.
Moreover, Foxp31CD41CD25high regulatory
T cells (Tregs) are known to be major regulators of
adaptive immunity [11]. Given the pathophysiological
link between GVHD and immune reconstitution
[12,13], protection against GVHD by Tregs might
potentially promote a timely and complete immune
recovery [14], as we reported previously [15]. In partic-
ular, in vitro studies have shown that Tregs inhibit the
activation of both CD41 and CD81 conventional
CD252 T cells by acting directly on target T cells or
on antigen-presenting cells [16,17]. In view of the
close functional correlation between Tregs and
CD31 T cells in the allo-PBSCT setting, in the pres-
ent study, we investigated the contribution of these
two cell populations to aGVHD and immunologic re-
covery by calculating the numerical index of the
CD31/Tregs ratio in donor grafts gCD3/Tregs R.PATIENTS AND METHODS
The study included 65 consecutive patients who
underwent allo-PBSCT between February 2005 and
December 2009. Written informed consent was
obtained from all patients. Patient characteristics are
summarized in Table 1. All patients received a PBSC
graft from an HLA-identical sibling donor (n5 45) or
an unrelated HLA-identical donor (matched unrelated
donor [MUD]) (n 5 20). High-resolution (four digits)
DNA-based HLA typing of donor and recipient was
done for HLA-A, -B, -C, -DRB1, and -DQB1. In
MUD transplantations, a complete match (10 of 10)
was documented in 15/20 (75%) donor–patient pairs
and a mismatch (nine of 10) in five/20 pairs (25%). All
patients received a conventional myeloablative condi-
tioning regimen that included16mg/kgoforal busulfan
and 120mg/kg of cyclophosphamide, with 7.5mg/kg of
rabbit antithymocyte globulin (rATG [Thymoglobu-
line]) in MUD transplantations. All patients received
prophylactic antibiotics (levofloxacin 500 mg daily)
until neutrophil engraftment, along with fluconazole
(400 mg daily to day 1100) for antifungal prophylaxis
and trimethoprim-sulfamethoxazole for Pneumocystis
carinii prophylaxis.
All patients received GVHD prophylaxis using
cyclosporin A (starting on day –1 before allo-PBSCT)
and methotrexate (on days 11, 13, 16, and 111 after
allo-PBSCT). Heparinized blood samples were
obtained at 1, 2, 3, and 6 months posttransplantation
for cytometric Tregs, cytomegalovirus (CMV)-specific
CD81 T cells, and absolute neutrophil counts. Tregs
were also evaluated in those patients with aGVHD
during the 3 months after allo-PBSCT, immediatelyat the onset of aGHVD before initiation of treatment.
The HLA genotype was HLA-A01 in 11 patients,
HLA-A02 in 32 patients, HLA-B01 in two patients,
HLA-B02 in fourpatients, andHLA-B35 in16patients.
Mobilization
For mobilization of CD341 cells in the peripheral
blood, all healthy donors received lenograstim or
filgrastim 10 mg/kg/day for 5 days.
Graft Content
The numbers of total nucleated, CD341, CD31,
CD41, CD81, NK, and Treg cells in the donor graft
were assessed before PBSC infusion. Tregs were phe-
notypically analyzed by flow cytometry using a panel of
directly conjugated antibodies to CD3, CD4, CD25
(M-A251), and CD45RO. FITC, PE, PerCP, and allo-
phycocyanin (Beckman Coulter, Miami, FL and BD
Biosciences, Franklin Lakes, NJ) were used as fluoro-
phores. Intracellular analysis of FoxP3 (eBioscience,
San Diego, CA) was performed after fixation and per-
meabilization according to the manufacturer’s recom-
mendations. Flow cytometry was performed with
a FACSCalibur flow cytometer (BD Biosciences),
and data were acquired and analyzed using Cellquest
software. NK lymphocytes, identified as CD32 and
CD16 and/or CD561 cells, were analyzed using amul-
ticolor flow cytometric panel with B, T, and NK cell
markers (BD Multitest 6-color TBNK reagent; BD
Biosciences). Absolute count determination of viable
total nucleated cells and CD341 cells was performed
using FlowCount beads solution on a Cytomics
FC500 flow cytometer (Beckman Coulter) according
to the International Society of Hematotherapy and
Graft Engineering protocol.
Evaluation of gCD3/Tregs R
The gCD3/Tregs R was calculated for all patients
at the time of PBSC infusion. Receiver-operating char-
acteristic (ROC) curve analysis was performed to
Table 2. Comparison of Patients in the HR and LR Groups
HR Group
(n 5 26)
LR Group
(n 5 39) P value
Median age, years 37 35 NS
Median gCD3/Tregs R value 77 15 <.001
Sex mismatch, n (%) 15 (58) 22 (56) NS
Donor, n (%) NS
Sibling 18 (69) 27 (69)
MUD 8 (31) 12 (31)
rATG use, n (%) NS
Yes 8 (31) 12 (31)
No 18 (69) 27 (69)
GVHD prophylaxis: cyclosporin +
methotrexate, n (%)
26 (100) 39 (100) NS
Table 3. Cellular Composition of the 65 Allografts
Median value (Range) 
106/Kg
Total nucleated cells 57 (13-127)
CD34+ 5.2 (3.7-9)
CD3+ 256 (67-550)
CD4+ 135 (46-312)
CD8+ 74 (37-219)
Natural killer cells 38 (17-260)
Tregs 12 (2-21)
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appearance of aGVHD. The cohort was divided into
two groups based on gCD3/Tregs R value: low
gCD3/Treg R (\36; LR group) and high gCD3/
Tregs R ($36; HR group) (Table 2).
Tetramer Staining and CMV-Specific Immune
Response Recovery
Fluorochrome-conjugated tetrameric was used as
reported previously [15]. Here, 5 mL of CD8-FITC,
CD3-PC5, and PE-conjugated tetrameric HLA (ac-
cording to the patients’ HLA status), purchased from
Beckman Coulter, was added to 100 mL of heparinized
blood and incubated for 30 minutes. After RBC lysis,
samples were washed and acquired on a Cytomics
FC500 flow cytometer (Beckman Coulter). CD31/
CD81 lymphocytes (5  103) were stored, and the
tetramer-positive fraction was defined as CMV-
specificCD81Tcells.CMV-specific immune response
recovery was defined as reported previously [15].
Preventing CMV Infection and Disease
Measures to prevent CMV infection and disease
were instituted as described previously [15].
aGVHD Diagnosis and Treatment
aGVHDwasdiagnosedbasedon clinical symptoms
and/or analysis of biopsy specimens from skin, oral
mucosa, liver, and gut and classified according to the
standard Seattle criteria [18]. All patients with aGVHD
grade II or greater were treated with methylpredniso-
lone at an initial dose of 1 to 2 mg/kg body weight,
with the dose then adjusted according to the clinical re-
sponse. Corticosteroid therapy at doses exceeding 1
mg/kg/day was administered in 10 patients (33%)
with aGVHD, three in the LR group and seven in the
HR group (37% versus 32%; P5 not significant [NS]).
Statistical Analysis
The Mann-Whitney rank-sum test was used for
comparisons of absolute cell counts between the two
groups. The two-tailed Fisher exact test was per-
formed to compare categorical variables; the Pearsonproduct was used to study correlations. Logistic re-
gression was used for multivariate analysis.
The discriminatory power of the gCD3/Tregs R to
detect aGVHD onset was assessed by estimating the
area under the ROC curve (AUC), using the trapezoi-
dal method on a ‘‘training’’ sample (study cohort) and
then on a separate ‘‘validation’’ sample. The optimal
cutoff was determined by maximizing both sensitivity
and specificity. Here, sensitivity and specificity, com-
puted at the optimal cutoff, are reported along with
95% confidence intervals (CIs). Differences between
the AUCs for two independent ROC curves were
tested using the method of Hanley and McNeil [19].
A P value #.05 was considered statistically significant.
All analyses were performed using SAS 9.1 (SAS Insti-
tute, Cary, NC) and R version 2.12 statistical software.RESULTS
Graft Content, gCD3/Tregs R, and aGVHD
The Tregs and CD31 T cell median values
in allografts were 12  106/kg of the recipient (range,
2-21 106/kg) and 256 106/kg (67-550 106/kg), re-
spectively (Table 3). Graft Tregs (gTregs) did not cor-
relate with total nucleated, CD341, CD31, CD41,
CD81, andNK cell numbers (Table 3 presents median
values). The median gCD3/Tregs R was 18 (range, 8-
250), and the overall incidence of grade II-IV aGVHD
was 46% (30/65; 44% in sibling donors and 50% in
MUDs). There were 26 patients (40%) in the HR
group and 39 (60%) in the LR group (Table 2). The in-
cidence of aGVHDdid not differ significantly between
MUD and sibling donor transplantations (50% [10 of
20] versus 44% [20 of 45]; P5NS). Low gCD3/Tregs
R was associated with a significantly decreased inci-
dence of grade II-IV aGVHD (20% [eight of 39] versus
84% [22 of 26]; P\ .001). Analysis of transplantations
subdivided into sibling donor and MUD transplanta-
tions confirmed the lower incidence of grade II-IV
aGVHDin theLRgroup comparedwith theHRgroup
(22% versus 78%; P\ .001; 17% versus 100%, P\
.001). Analysis of transplantations subdivided accord-
ing to whether or not patients received rATG revealed
no difference either in gCD3/TregsRmedian value (17
versus 18; P5NS) or incidence of a GVHD (55% [11
of 20] versus 44% [20 of 45]; P 5NS).
Figure 1. Correlation between gTregs and peripheral blood Tregs.
Dots correspond to samples from patients in the second month corre-
lated with the gTregs at the time of graft reinfusion. A significant positive
correlation was seen between gTregs and peripheral blood Tregs, as
shown by the trend line (r 5 0.36; P 5 .003).
Figure 3. Median value of circulating peripheral blood Tregs in the LR
and HR groups.
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Training set (Study cohort)
The training sample comprised 65 patients under-
going allo-PBSCT (study cohort). AUC analysis
(AUC, 0.79; 95% CI, 0.683-0.898) identified 36 as
the optimal gCD3/Tregs R cutoff value for detecting
the presence of aGVHD, with 71% sensitivity (95%
CI, 53.4%-83.9%) and 94% specificity (95% CI,
80.9%-98.4%).
Validation set
The validation sample comprised 31 patients who
underwent allo-PBSCT. AUC analysis (AUC, 0.85;
95% CI, 0.6725-1.023) identified 40 as the optimal
gCD3/Tregs R cutoff value for detecting the presence
of aGVHD, with 82% sensitivity (95% CI, 52.3%-
94.9%) and 90% specificity (95% CI, 69.9%-97.2%).
There was no statistically significant difference be-
tween the two AUCs (P 5 .561).
gTregs, gCD3/Tregs R, and Peripheral Blood
Tregs
We found a correlation between peripheral blood
Tregs with both gTregs and gCD3/Tregs R at 1Figure 2. Correlation between gCD3/Tregs R and peripheral blood
Tregs. Dots correspond to samples from patients in the second month
correlated with the gCD3/Tregs R at the time of graft reinfusion. A sig-
nificant positive correlation was seen between cCD3/Tregs R and pe-
ripheral blood Tregs, as shown by the trend line (r 5 0.38; P 5 .002).month (r 5 0.37, P 5 .003; r 5 0.39, P 5 .002),
2 months (r 5 0.36, P 5 .003; r 5 0.38, P 5 .002,
Figures 1 and 2), and 3 months (r 5 0.40, P 5 .002;
r 5 0.41, P 5 .002).
Peripheral Blood Tregs and CMV-specific CD81
T Lymphocytes Evaluation
The peripheral blood median value of Tregs was
significantly higher in the LR group than in the HR
group at 1, 2, and 3 months after allo-PBSCT
(Figure 3). Median CMV-specific CD81 T lympho-
cytes were also significantly higher in the LR group
at 1 month (2 cells/mL versus 0 cells/mL; P\ .001),
2 months (6 cells/mL versus 1 cell/mL; P\ .001), and
3 months (15 cells/mL versus 3 cells/mL; P \ .001)
(Figure 4). There was no difference between patients
who received rATG and those who did not in terms
of peripheral blood median values of Tregs and
CMV-specific CD81 T lymphocytes at 1, 2, and
3 months (Figures 5 and 6).
CMV Infection/Disease
During the first 3 months after allo-PBSCT, CMV
infection/disease was observed in six of 39 patients
(15%) in the LR group and in 18 of 26 patients
(69%) in the HR group (P\ .001).
Multivariate Logistic Regression
On univariate analysis, HLAmismatch and gCD3/
Tregs R were correlated with aGVHD, and gCD3/
Tregs R, donor CMV serology, and aGVHD were
correlated with CMV infection/disease. On multivari-
ate logistic regression, gCD3/Tregs R was correlated
with both aGVHD (odds ratio [OR], 2.50; 95% CI,
1.30-4.50; P 5 .05) and CMV infection (OR, 2.35;Figure 4. Median value of circulating CMV-specific CD81 T cells in the
LR and HR groups.
Figure 5. Median value of circulating peripheral blood Tregs in patients
receiving rATG (rATG1) and those not receiving rATG (rATG2).
Table 4. Univariate Analysis of Potential Factors Affecting
Grade II-IV aGVHD and CMV Infection/Disease
Factor
Grade II-IV aGVHD,
P value
CMV Infection/Disease,
P value
HLA mismatch, yes/no .02 NS
ATG use, yes/no NS NS
gCD3/Tregs R, H/L <.001 <.001
Donor type, MUD/sibling NS NS
Donor age NS —
Donor CMV serology,
high risk/not high risk
— <.001
aGVHD (grade II-IV), yes/no — <.001
Conditioning regimen intensity: 100% full ablative; transplantation
source: 100% PBSC.
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among donor CMV serology, aGVHD, and CMV in-
fection/disease (data summarized in Tables 4 and 5).
Relapse Rate
The relapse rate at 1.5 years was not significantly
affected by the number of transplanted Tregs (15%
in the LR group versus 20% in theHRgroup;P5NS).DISCUSSION
In the present study, we evaluated the correlation
between gCD3/Tregs R and the incidence of aGVHD
in a homogeneous series (identical conditioning regi-
men and GVHD prophylaxis) of 65 consecutive pa-
tients who underwent allo-PBSCT. The incidence of
aGVHD was lower in the LR group compared with
the HR group, both in sibling and in MUD transplan-
tations. This observation is in line with other reports
showing a correlation between Tregs content in the
allograft and the risk of aGVHD [20-23]. In
contrast, Stanzani et al. [24] reported a positive corre-
lation between CD41 and CD81 T cells coexpressing
CD25 with the incidence of aGVHD; however, they
examined a heterogeneous population of patients in
terms of conditioning regimens and GVHD prophy-
laxis, whereas our patient cohort was homogeneous
for GVHD prophylaxis and conditioning regimen
(100% full myeloablative). We deliberately excluded
reduced-intensity conditioning transplantations from
our analysis, because immunologic differences might
account for the lack of a significant effect of the graft
Tregs content on the aGVHD incidence in nonmye-
loablative transplantations. In fact, reduced-intensityFigure 6. Median value of circulating CMV-specific CD81 T cells in pa-
tients receiving rATG (rATG1) and those not receiving rATG (rATG2).conditioning is characterized by a longer period of
both donor/host cell chimerism and of aGVHD ap-
pearance after stem cell transplantation [25]. In con-
trast, in myeloablative PBSCT, we hypothesize that
a rapid activation of aGVHD-inducing CD31 T cell
clones might be suppressed more efficiently in the
presence of high numbers of transplanted Tregs.
The delicate balance between CD3 alloreactive T cells
and Tregs in both GVHD and immunologic toler-
ance, demonstrated by the gCD3/Tregs R, might be
crucial for the development of aGVHD. Moreover,
our ROC analysis revealed that the gCD3/Tregs R
value might help predict patients at risk for aGVHD
at the time of infusion.
Of note, 25% of MUD transplantations had 9/10
HLAmatching, which could constitute a limit in terms
of heterogeneity of the study cohort compared with
10/10 matched or sibling transplantations, especially
given the use of rATG in the setting of MUD trans-
plantations. However, analysis of transplantations ac-
cording to the use of rATG revealed no significant
difference in gCD3/Tregs R median value (17 versus
18; P 5 NS) or in incidence of aGVHD (55% [11 of
20] versus 44% [20 of 45]; P 5 NS). In addition, pe-
ripheral blood Tregs and CMV-specific CD81T cell
recovery were not statistically different between pa-
tients receiving rATG and those not receiving rATG
(Figures 5 and 6). rATG might promote not only
depletion but also expansion, of T cells number and
function [26], thus justifying the similar incidence of
aGVHD inMUD transplantations compared with sib-
ling transplantations (50% [10 of 20] versus 44% [20 of
45]; P 5 NS). Of note, rATG use was comparable inTable 5. Multivariate Analysis of Factors Affecting Grade II-
IV aGVHD and CMV Infection/Disease
Factor
Grade II-IV aGVHD CMV Infection/Disease
OR (95% CI) P value OR (95% CI) P value
HLA mismatch, yes/no 2.10 (1.35-5.00) .06 — —
gCD3/Tregs R, H/L 2.50 (1.30-4.50) .05 2.35 (0.9-5.00) .05
Donor CMV serology,
high risk/not high risk
— — 2.20 (1.30-4.00) .05
aGVHD (grade Il-IV),
yes/no
— — 2.70 (1.35-5.50) .006
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initial contribution of graft CD3/Tregs R to GVHD
and immune reconstitution might not be affected by
later rATG administration. Finally, proof that ATG
clearly affects immune reconstitution has not been
shown by multivariate analysis in large cohorts of pa-
tients undergoing transplantation [27].
In healthy donors, CD31 cells and Tregs account
for 45% to 79% and 0.7% to 5% of mononuclear pe-
ripheral blood cells, respectively, with considerable
individual variation. This leads to a considerable vari-
ability in the cellular composition of infused allogeneic
peripheral blood cells. Previous in vitro experiments
have shown that the relative proportion of Tregs to
the number of effector T cells determines their immu-
nologic activity [28]. Of note, our data show correla-
tions between peripheral blood Tregs and both
gTregs and gCD3/Tregs R (Figures 1 and 2),
suggesting that the ratio might serve as a good tool
for predicting a rise in peripheral blood Tregs (as well
as gTregs) while maintaining the higher values needed
for immunologic recovery (Figure 3 and 4). In fact,
we previously showed [15] a correlation between
peripheral blood Tregs and protection against CMV;
thus, the ratiomight distinguishpatientswith immunity
against CMV from those without, at 1, 2, and 3 months
(Figure 4) despite a graft-related approach (ie, steroids).
Corticosteroid therapy has been clearly demonstrated
to have a dose- and time-dependent detrimental effect
on CD81T cell function at 3 months after transplanta-
tion [27], particularly at doses of .1 mg/kg/day, and
a cumulative 1-month dosage of.10mg/kg is believed
to affect CD81 T cell immunity. In our cohort of
patients, corticosteroid therapy at doses exceeding
1 mg/kg/day was administered in 10 (33%) aGVHD
transplant patients, three in the LR group and seven
in theHRgroup (37%versus 32%;P5NS).Therefore,
in our setting, steroid use due to aGVHD therapy did
not seem to have an impact on CD81 T cell function.
In contrast, it should also be noted that apart from
steroids, the use of bone marrow as a stem cell source
also has been shown to affect CD81 reconstitution
[27]. However, peripheral blood was the sole stem cell
source in the present study. After allogeneic transplan-
tation, Tregs are known to preserve the thymic and
peripheral lymphnode architecture, thereby promoting
accelerated donor lymphoid reconstitution, which can
be more effective against CMV [14].
The relapse rate in our cohort was not affected by
the number of transplanted Tregs. This observation
fits the concept proposed by Edinger et al. [21] in
a mouse model that Tregs are potent inhibitors of
GVHD while maintaining the GVL effect.
Taken together, our data suggest a good correla-
tion between gCD3/Tregs R value and both aGVHD
and immunologic recovery after myeloablative allo-
PBSCT. Future perspectives might envisage the possi-bility ofmodifying the ratio by reducingCD31 cells (by
in vivo or in vitro depletion) while preserving theTregs
component (by the addition of donor-derived Tregs).ACKNOWLEDGMENTS
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